Who Paid My Doc
David Kloth
Danbury, CT Medical Doctor
NPI 1336137058 CMS profile 15126
109 Newtown Rd, Suite 1, Danbury, CT 06810
General payments
$167,474
Research payments
$0
Ownership & investment interest
$100
Through program year 2025, David Kloth of Danbury, CT is reported in the CMS Open Payments database as having received $167,474 across 147 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $100 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $267 | 4 | |
| 2024 | General | $553 | 8 | |
| 2023 | General | $120,256 | 24 | |
| 2022 | General | $922 | 18 | |
| 2021 | General | $611 | 11 | |
| 2020 | General | $905 | 12 | |
| 2019 | General | $43,961 | 70 | |
| 2019 | Ownership | $100 | 1 |
Beside peers
- David Kloth
- Connecticut median
- Middle half of Connecticut
- National median
In program year 2025, general payments to David Kloth were reported at $267. Among 12,665 Connecticut profiles paid that year, the median was $167 and the middle half received between $54 and $639.
Show as a table
| Year | David Kloth | Connecticut median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $43,961 | $163 | $50–$671 | $163 |
| 2020 | $905 | $111 | $33–$382 | $114 |
| 2021 | $611 | $124 | $39–$443 | $132 |
| 2022 | $922 | $138 | $45–$535 | $149 |
| 2023 | $120,256 | $148 | $47–$556 | $160 |
| 2024 | $553 | $157 | $49–$599 | $164 |
| 2025 | $267 | $167 | $54–$639 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 30 drugsPart D claims
3,680
Drug cost
$177,853
Branded share of claims
35.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Percocet Oxycodone Hcl/Acetaminophen | Brand | 13 | $41,136 | |
| Oxycontin Oxycodone Hcl | Brand | 46 | $40,173 | |
| Nucynta Tapentadol Hcl | Brand | 15 | $24,435 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 674 | $17,343 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 404 | $9,828 | |
| Oxycodone Hcl | Generic | 580 | $8,694 | |
| Nucynta Er Tapentadol Hcl | Brand | 16 | $7,593 | |
| Gabapentin | Generic | 380 | $6,051 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 129 | $3,284 | |
| Pregabalin | Generic | 125 | $2,966 |
The 10 drugs with the highest cost, of 30 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 76 billing codesPaid by Medicare
$393,944
Medicare patients
456
Services billed
25,292
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 71% | |
| Ischemic heart disease | 34% | |
| Diabetes | 27% | |
| Depression | 27% | |
| Chronic kidney disease | 22% | |
| Atrial fibrillation | 16% | |
| Osteoporosis | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 | Office | 19 | 1,200 | $8,167 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 245 | 14,751 | $1,471 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 123 | 1,380 | $1,074 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 50 | 59 | $297 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 245 | 403 | $116 |
| Injection, methylprednisolone acetate, 20 mg J1020 | Office | 18 | 20 | $110 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 12 | 12 | $84 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 29 | 550 | $50 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
147 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.